keyword
https://read.qxmd.com/read/30906479/effects-of-olanzapine-on-cytokine-profile-and-brain-derived-neurotrophic-factor-in-drug-naive-subjects-with-first-episode-psychosis
#21
JOURNAL ARTICLE
Erifili Hatziagelaki, Anastasia Tsiavou, Charilaos Gerasimou, George D Vavougios, Aris Spathis, Efstathios Laskos, Charalabos Papageorgiou, Athanasios Douzenis, Nikos Christodoulou, Nicolaos Stefanis, Demetrios A Spandidos, Nikolaos Nikolakakis, Konstantinos Tsamakis, Emmanouil Rizos
Immunological abnormalities have been implicated in schizophrenia. On the other hand, antipsychotics may exert immunomodulatory effects, by triggering pro-inflammatory and anti-inflammatory agents through complex homeostatic mechanisms, which seem to be implicated in medication responsiveness and in the presence or not of adverse effects. There is evidence that olanzapine, a second generation antipsychotic, may increase synapse formation and neurogenesis through alterations in the levels of cytokines and neurotrophic factors...
April 2019: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/30802709/antipsychotics-differentially-regulate-insulin-energy-sensing-and-inflammation-pathways-in-hypothalamic-rat-neurons
#22
JOURNAL ARTICLE
Chantel Kowalchuk, Pruntha Kanagasundaram, Denise D Belsham, Margaret K Hahn
INTRODUCTION: Second generation antipsychotic (AP)s remain the gold-standard treatment for schizophrenia and are widely used on- and off-label for other psychiatric illnesses. However, these agents cause serious metabolic side-effects. The hypothalamus is the primary brain region responsible for whole body energy regulation, and disruptions in energy sensing (e.g. insulin signaling) and inflammation in this brain region have been implicated in the development of insulin resistance and obesity...
June 2019: Psychoneuroendocrinology
https://read.qxmd.com/read/30526722/homa-ir-increase-after-antidepressant-treatment-in-depressed-patients-with-the-met-allele-of-the-val66met-bdnf-genetic-polymorphism
#23
JOURNAL ARTICLE
Séverine Martin, Romain Colle, Khalil El Asmar, Adrien Rigal, Albane Vievard, Bruno Feve, Laurent Becquemont, Céline Verstuyft, Emmanuelle Corruble
BACKGROUND: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with response to antidepressant drugs in depressed patients and with metabolic side effects after antipsychotic treatment. This study aims to assess the association between this polymorphism and insulin resistance after antidepressant treatment in depressed patients. METHODS: One hundred forty-eight Caucasian patients with a current unipolar major depressive episode (DSM IV-TR) were genotyped for the BDNF Val66Met polymorphism and assessed at baseline and after 3 and 6 months of antidepressant treatment for the 'Homoeostasis model assessment of insulin resistance' (HOMA-IR) index, a valid measure of insulin resistance based on fasting plasma insulinaemia and glycaemia...
October 2019: Psychological Medicine
https://read.qxmd.com/read/30384401/effects-of-asenapine-and-paliperidone-on-depression-anxiety-and-analgesy-in-mice-alterations-in-brain-neurotrophic-factors-neurogenesis-and-blood-enzyme-levels
#24
JOURNAL ARTICLE
Esen Gumuslu, Oguz Mutlu, Sibel Kokturk, Guner Ulak, Fatma Ceyla Eraldemir, Ozan Can Tatar, Alisan Burak Yasar, Pelin Tanyeri, Furuzan Akar, Faruk Erden
Schizophrenia, an important brain neurodevelopmental disorder, is observed in 1% of the global population. New-generation antipsychotics have been developed as alternatives to typical antipsychotics for more effective and safe therapy. Chronic administration of asenapine and paliperidone compared to haloperidol on depression, anxiety and analgesy in the forced swimming test (FST), elevated plus maze (EPM) and hot plate tests were examined in mice. Moreover effects of drugs, on expression levels of brain neurotrophic factors [brain-derived neurotrophic factor (BDNF), cAMP response element binding protein (CREB),nerve growth factor (NGF), synapsin and fibroblast growth factor 2 (FGF2)] in the hippocampus of mice, neurogenesis and neurodegeneration, and blood enzyme levels were also investigated...
October 31, 2018: Chinese Journal of Physiology
https://read.qxmd.com/read/30312750/bdnf-as-a-pharmacogenetic-target-for-antipsychotic-treatment-of-schizophrenia
#25
REVIEW
Mei Han, Chao Deng
Antipsychotic drugs remain the mainstay of pharmacotherapy for schizophrenia. As there are large individual variations in efficacy and side-effects of antipsychotic drugs, there is a strong demand for personalized medication to treat schizophrenia. Pharmacogenetic research into antipsychotic drugs has examined a number of genetic variants and only a few polymorphisms have been found which promise to be associated with the therapeutic efficacy and side-effects of antipsychotic drugs. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several neurotransmitter systems including the dopaminergic system involved in the pathophysiology of schizophrenia...
October 9, 2018: Neuroscience Letters
https://read.qxmd.com/read/30214393/camp-response-element-binding-protein-creb-a-possible-signaling-molecule-link-in-the-pathophysiology-of-schizophrenia
#26
REVIEW
Haitao Wang, Jiangping Xu, Philip Lazarovici, Remi Quirion, Wenhua Zheng
Dopamine is a brain neurotransmitter involved in the pathology of schizophrenia. The dopamine hypothesis states that, in schizophrenia, dopaminergic signal transduction is hyperactive. The cAMP-response element binding protein (CREB) is an intracellular protein that regulates the expression of genes that are important in dopaminergic neurons. Dopamine affects the phosphorylation of CREB via G protein-coupled receptors. Neurotrophins, such as brain derived growth factor (BDNF), are critical regulators during neurodevelopment and synaptic plasticity...
2018: Frontiers in Molecular Neuroscience
https://read.qxmd.com/read/30181602/bdnf-val66met-polymorphism-and-clinical-response-to-antipsychotic-treatment-in-schizophrenia-and-schizoaffective-disorder-patients-a-meta-analysis
#27
JOURNAL ARTICLE
Eric Huang, Nuwan C Hettige, Gwyneth Zai, Julia Tomasi, Justin Huang, Clement C Zai, Nela Pivac, Matea Nikolac Perkovic, Arun K Tiwari, James L Kennedy
Brain-derived neurotrophic factor (BDNF) plays an important role in dopaminergic and serotonergic neurotransmission by modulating dopaminergic neuron differentiation and establishment. Multiple studies have analyzed the functional BDNF Val66Met variant in relation to antipsychotic response in schizophrenia (SCZ) patients, yielding mixed results. A meta-analysis was thus performed to examine the relationship between this variant and symptom improvement during antipsychotic treatment. Searches using PubMed, Web of Science, and PsycInfo until October 2017 yielded 11 studies that met inclusion criteria (total n = 3774)...
June 2019: Pharmacogenomics Journal
https://read.qxmd.com/read/29332095/both-serum-brain-derived-neurotrophic-factor-and-interleukin-6-levels-are-not-associated-with-therapeutic-response-to-lamotrigine-augmentation-therapy-in-treatment-resistant-depressive-disorder
#28
JOURNAL ARTICLE
Shoko Kagawa, Kazuo Mihara, Takeshi Suzuki, Goyo Nagai, Akifumi Nakamura, Kenji Nemoto, Tsuyoshi Kondo
BACKGROUND/AIMS: Serum levels of brain-derived neurotrophic factor (BDNF) and interleukin-6 (IL-6) were prospectively monitored in relation with therapeutic response to lamotrigine augmentation therapy in 46 (15 males and 31 females) inpatients with treatment-resistant depressive disorder during an 8-week treatment with lamotrigine using an open-study design. METHODS: The subjects were 46 depressed patients who had already shown insufficient response to at least 3 psychotropics including antidepressants, mood stabilizers, and atypical antipsychotics...
2017: Neuropsychobiology
https://read.qxmd.com/read/28951142/cognitive-deficit-in-patients-with-paranoid-schizophrenia-its-clinical-and-laboratory-correlates
#29
JOURNAL ARTICLE
Mariia Dorofeikova, Nikolay Neznanov, Nataliia Petrova
The aim of this study was to search for correlates of cognitive impairment in patients with paranoid schizophrenia among clinical, demographic, anamnestic and biochemical markers (NSE, S100B protein, BDNF, hs-CRP). Patients with paranoid schizophrenia (n=125) were examined using the Brief Assessment of Cognitive Function in Schizophrenia, the Rey-Osterrieth Complex Figure task, and a number of clinical scales including the Positive and Negative Syndrome Scale. The majority of patients demonstrated cognitive impairment...
April 2018: Psychiatry Research
https://read.qxmd.com/read/28671000/brain-derived-neurotrophic-factor-serum-and-plasma-levels-in-the-treatment-of-acute-schizophrenia-with-olanzapine-or-risperidone-6-week-prospective-study
#30
JOURNAL ARTICLE
Suzan Kudlek Mikulic, Alma Mihaljevic-Peles, Marina Sagud, Maja Bajs Janovic, Lana Ganoci, Jasmina Grubisin, Martina Kuzman Rojnic, Bjanka Vuksan Cusa, Zoran Bradaš, Nada Božina
Antipsychotics have been the mainstay of the treatment of schizophrenia, and their potential role in neuroprotection could be related to brain-derived neurotrophic factor (BDNF). So far different effects on both serum and plasma levels of BDNF were reported related to the various antipsychotic treatments. Aim of this study was to investigate the influence of olanzapine or risperidone on both plasma and serum levels of BDNF in patients with acute schizophrenia. For 50 participants with acute episode of schizophrenia both plasma and serum BDNF, along with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression scale, were assessed pretreatment and post treatment - after 6 weeks of either risperidone or olanzapine...
October 2017: Nordic Journal of Psychiatry
https://read.qxmd.com/read/28624596/repeated-co-treatment-with-antidepressants-and-risperidone-increases-bdnf-mrna-and-protein-levels-in-rats
#31
JOURNAL ARTICLE
Zofia Rogóż, Katarzyna Kamińska, Patrycja Pańczyszyn-Trzewik, Magdalena Sowa-Kućma
BACKGROUND: Recently, several clinical studies have suggested a beneficial effect of a combination of antidepressants (ADs) with antipsychotic drugs in drug-resistant depression. Moreover, preclinical and clinical studies indicated a role of brain-derived neurotrophic factor (BDNF) in the pathology of depression, as well as in the mechanism of action of ADs. METHODS: In the present study, we investigated the effect of repeated administration of ADs, escitalopram, fluoxetine or mirtazapine and a low dose of risperidone (an atypical antipsychotic drug) given separately or in combination, on the mRNA and protein levels of BDNF or cAMP response element binding (p-CREB) in the hippocampus and frontal cortex of male Wistar rats...
October 2017: Pharmacological Reports: PR
https://read.qxmd.com/read/28599751/association-between-serum-levels-of-glutamate-and-neurotrophic-factors-and-response-to-clozapine-treatment
#32
JOURNAL ARTICLE
Amir Krivoy, Eldar Hochman, Kyra-Verena Sendt, Sarah Hollander, Yael Vilner, Mirjana Selakovic, Abraham Weizman, Michal Taler
Clozapine is the only available therapy for about 30% of schizophrenia patients otherwise refractory to antipsychotics. Unfortunately, the mechanism of action of the drug is still unknown and there are no biomarkers that can predict a positive response to clozapine. We aimed to examine serum neurotrophins and glutamate levels as putative biomarkers for clozapine response based on the hypothesized mode-of-action of the compound. Blood samples of 89 chronic schizophrenia patients maintained on clozapine were analyzed in a cross-sectional design...
February 2018: Schizophrenia Research
https://read.qxmd.com/read/28508933/genetic-variants-within-key-nodes-of-the-cascade-of-antipsychotic-mechanisms-effects-on-antipsychotic-response-and-schizophrenia-psychopathology-in-a-naturalistic-treatment-setting-in-two-independent-korean-and-italian-samples
#33
JOURNAL ARTICLE
Marco Calabrò, Stefano Porcelli, Concetta Crisafulli, Sheng-Min Wang, Soo-Jung Lee, Changsu Han, Ashwin A Patkar, Prakash S Masand, Diego Albani, Ilaria Raimondi, Gianluigi Forloni, Sofia Bin, Alessandro Mattiaccio, Vilma Mantovani, Tae-Youn Jun, Chi-Un Pae, Alessandro Serretti
INTRODUCTION: Schizophrenia (SCZ) is one of the most disabling psychiatric disorders. Genetic factors play an important role in both SCZ liability and its treatment outcome. In the present paper, we investigated the effects of several single nucleotide polymorphisms (SNPs) within ten strong candidate genes involved with antipsychotics (APs) mechanisms of action. METHODS: Two independent samples were investigated in the present study. Totals of 176 SCZ subjects and 326 controls of Korean ancestry, and 83 SCZ subjects and 194 controls of Italian ancestry were recruited and genotyped...
June 2017: Advances in Therapy
https://read.qxmd.com/read/28410959/the-involvement-of-bdnf-creb-signaling-pathways-in-the-pharmacological-mechanism-of-combined-ssri-antipsychotic-treatment-in-schizophrenia
#34
JOURNAL ARTICLE
Reef Einoch, Orly Weinreb, Nina Mandiuk, Moussa B H Youdim, Warren Bilker, Henry Silver
Previous studies into the mechanism of SSRI-antipsychotic synergism in our laboratory identified unique changes in the brain, particularly in the γ-aminobutyric acid (GABA)-A receptor and its modulators. This study examined the role of brain derived neurotrophic factor (BDNF)-cAMP response element binding (CREB) protein signaling pathways, including protein kinase B (AKT), glycogen synthase kinase (GSK)-3β and related molecules in the molecular response to haloperidol, fluvoxamine, combined haloperidol+fluvoxamine and clozapine treatments in rat frontal cortex, hippocampus and primary cortical neuronal cultures...
May 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/28335658/dopamine-antagonists-for-treatment-resistance-in-autism-spectrum-disorders-review-and-focus-on-bdnf-stimulators-loxapine-and-amitriptyline
#35
REVIEW
Jessica A Hellings, L Eugene Arnold, Joan C Han
Drug development and repurposing are urgently needed for individuals with autism spectrum disorders (ASD) and psychiatric comorbidity, which often presents as aggression and self-injury. Areas covered: We review dopamine antagonists, including classical and atypical, as well as unconventional antipsychotics in ASD. The older antipsychotic loxapine is discussed in terms of preliminary albeit limited evidence in ASD. Emerging promise of amitriptyline in ASD is discussed, together with promising BDNF effects of loxapine and amitriptyline...
April 2017: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/27381554/the-%C3%AE-2c-adrenoceptor-antagonist-orm-10921-has-antipsychotic-like-effects-in-social-isolation-reared-rats-and-bolsters-the-response-to-haloperidol
#36
JOURNAL ARTICLE
Madeleine Uys, Mohammed Shahid, Jukka Sallinen, Walter Dreyer, Marike Cockeran, Brian H Harvey
Early studies suggest that selective α2C-adrenoceptor (AR)-antagonism has anti-psychotic-like and pro-cognitive properties. However, this has not been demonstrated in an animal model of schizophrenia with a neurodevelopmental construct. The beneficial effects of clozapine in refractory schizophrenia and associated cognitive deficits have, among others, been associated with its α2C-AR modulating activity. Altered brain-derived neurotrophic factor (BDNF) has been linked to schizophrenia and cognitive deficits...
November 3, 2016: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://read.qxmd.com/read/27042072/no-association-between-bdnf-val66met-polymorphism-and-treatment-response-in-obsessive-compulsive-disorder-in-the-japanese-population
#37
JOURNAL ARTICLE
Hidehiro Umehara, Shusuke Numata, Makoto Kinoshita, Shinya Watanabe, Shutaro Nakaaki, Satsuki Sumitani, Tetsuro Ohmori
AIM: Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, and it promotes the development and function of dopaminergic and serotonergic neurons. The Met allele of the BDNF Val66Met polymorphism is associated with a decrease in activity-dependent secretion of BDNF compared with the Val allele, and a number of studies have provided evidence for the association between this polymorphism and obsessive-compulsive disorder (OCD). The purpose of this study was to investigate whether this functional variant of the BDNF gene is associated with OCD and treatment response in patients with OCD in the Japanese population...
2016: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/26854986/bdnf-val66met-and-clinical-response-to-antipsychotic-drugs-a-systematic-review-and-meta-analysis
#38
REVIEW
S Cargnin, A Massarotti, S Terrazzino
BACKGROUND: The polymorphic brain-derived neurotrophic factor (BDNF) gene has been postulated to be involved in inter-individual variability response to antipsychotic drugs. PURPOSE: To perform a qualitative and quantitative synthesis of studies evaluating the influence of BDNF genetic variation on clinical response to antipsychotics. METHODS: The review protocol was published in the PROSPERO database (Reg. n(o) CRD42015024614). A comprehensive search was performed through PubMed, Web of Knowledge and Cochrane databases up to July 2015...
March 2016: European Psychiatry: the Journal of the Association of European Psychiatrists
https://read.qxmd.com/read/26130821/bdnf-and-ngf-signalling-in-early-phases-of-psychosis-relationship-with-inflammation-and-response-to-antipsychotics-after-1-year
#39
JOURNAL ARTICLE
M Martinez-Cengotitabengoa, K S MacDowell, S Alberich, F J Diaz, B Garcia-Bueno, R Rodriguez-Jimenez, M Bioque, E Berrocoso, M Parellada, A Lobo, P A Saiz, C Matute, M Bernardo, A Gonzalez-Pinto, J C Leza
Previous studies have indicated systemic deregulation of the proinflammatory or anti-inflammatory balance in individuals with first-episode psychosis (FEP) that persists 12 months later. To identify potential risk/protective factors and associations with symptom severity, we assessed possible changes in plasma levels of neurotrophins (brain-derived neurotrophic factor [BDNF] and nerve growth factor [NGF]) and their receptors in peripheral blood mononuclear cells (PBMCs). Expression of the 2 forms of BDNF receptors (active TrkB-FL and inactiveTrkB-T1) in PBMCs of FEP patients changed over time, TrkB-FL expression increasing by 1 year after diagnosis, while TrkB-T1 expression decreased...
January 2016: Schizophrenia Bulletin
https://read.qxmd.com/read/26076775/pharmacogenetics-and-antipsychotic-treatment-response
#40
REVIEW
Z Naumovska, A K Nestorovska, A Filipce, Z Sterjev, K Brezovska, A Dimovski, L J Suturkova
Antipsychotic drugs are widely used in the treatment of schizophrenia and psychotic disorder. The lack of antipsychotic response and treatment-induced side-effects, such as neuroleptic syndrome, polydipsia, metabolic syndrome, weight gain, extrapyramidal symptoms, tardive dyskinesia or prolactin increase, are the two main reasons for non-compliance and increased morbidity in schizophrenic patients. During the past decades intensive research has been done in order to determine the influence of genetic variations on antipsychotics dosage, treatment efficacy and safety...
2015: Prilozi (Makedonska Akademija Na Naukite i Umetnostite. Oddelenie za Medicinski Nauki)
keyword
keyword
70081
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.